Nov 07,2019

Livongo adjusts revenue guidance upward after Q3 full of new client wins

In its second earnings call as a public company, Livongo was able to report strong financial and operational numbers and raise its revenue guidance for the year from $7 million to $9.5 million. CEO Zane Burke also shared that the company's diversification beyond diabetes is making progress: more than 20% of the company's estimated value from new partnerships is from non-diabetes business.

View Analyst & Ambassador Comments
Go to original news
Nov 14,2019

BCBS of Minnesota inks deal with Omada to provide Type 2 diabetes tool to members

Digital chronic care platform Omada is deepening its relationship with Blue Cross and Blue Shield of Minnesota (Blue Cross), inking a new deal that provides the insurer’s commercial plan members access to the startup’s Type 2 diabetes care platform. As part of yesterday’s news, Blue Cross also announced it would be making a strategic investment in Omada; however, the actual value of this investment was not disclosed.

COLLABORATION PARTNERSHIP

#insurance

View Analyst & Ambassador Comments
Go to original news
Nov 15,2019

Livongo's diabetes, hypertension management program cuts down high blood pressure over 12 weeks

Livongo is touting new data regarding the efficacy of its device-and-coaching disease management platform, this time among those using its Livongo for Hypertension and Livongo for Diabetes products together. The study examined a cohort of 1,690 Livongo members with a diabetes diagnosis and hypertension. After 12 weeks of Livongo’s testing and coaching program, those whose hypertension was uncontrolled recorded decreases of 7.2 mmHg for systolic blood pressure, and 4.0 mmHg for diastolic blood pressure (P < .001).

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 20,2019

VA announces regional availability of Podimetrics' diabetic foot ulcer detection platform

The US Department of Veterans Affairs recently announced a regional rollout that it will make a connected device for diabetic foot ulcer detection available to veterans across the country as of December 1. The platform, developed by Somerville, Massachusetts-based Podimetrics, is already being used at 15 of the department’s medical centers, and according to the VA will also be included in an upcoming pilot program being implemented in the southeast part of the country.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Nov 01,2019

2019 Beyond Type Run Team to Race the TCS New York City Marathon Using Basal-IQ Technology from Tandem Diabetes Care

The Beyond Type Run team will be running the TCS New York City Marathon on November 3, 2019, and Tandem Diabetes Care has made the t:slim X2™ insulin pump with Basal-IQ® technology available to all team members.

View Analyst & Ambassador Comments
Go to original news
Nov 04,2019

Beyond Type 1 and One Drop Partner to Inspire and Empower People With Diabetes

Beyond Type 1, a nonprofit organization changing what it means to live with diabetes, and One Drop, a leader in the development of digital therapeutics solutions for diabetes, today announced a partnership designed to connect and empower the global diabetes community. Together, the two companies will collaborate on a year-long series of promotions, events, and campaigns that promote support for people everywhere living with diabetes.

COLLABORATION PARTNERSHIP

#institution

View Analyst & Ambassador Comments
Go to original news
Nov 04,2019

Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance

In comparing the third quarter of 2019 to the same period of 2018: Worldwide pump shipments increased 112 percent to 17,839 pumps from 8,434 pumps, and Sales increased 105 percent to $94.7 million from $46.3 million

View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

BD Announces Results For 2019 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2020 Guidance

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30, 2019. Company's Diabetes Care revenue is reported as $151 million, increased by %1 YoY.

View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year

Third quarter revenue of $192.1 million, up 27%, compared to revenue of $151.1 million in the prior year. The global Omnipod revenue of $177.2 million increased by 34% YoY.

View Analyst & Ambassador Comments
Go to original news
Nov 07,2019

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation today announced that management will present at two upcoming investor conferences: The 2019 Stephens Nashville Investment Conference in Nashville, TN on Wednesday, November 13, 2019, at 10:30 a.m. (Central Time) ; and The Piper Jaffray 31st Annual Healthcare Conference in New York City, NY on Wednesday, December 4, 2019, at 9:00 a.m. (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES